New animal research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment, ...

Participants who received tirzepatide, the active ingredient in Zepbound, also had greater reductions in waist size and more significant improvements in metabolic risk factors. Tirzepatide’s dual ...

Tirzepatide's dual mechanism targets GIP and GLP-1, so it provides strong cardiovascular benefits, said Stephen Nicholls, MBBS, PhD, MBA. The dual glucose-dependent insulinotropic polypeptide (GIP) ...

Please provide your email address to receive an email when new articles are posted on . The clinical benefits of tirzepatide in patients with HFpEF and obesity were consistent regardless of kidney ...

A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment. Study: Tirzepatide on ingestive behavior in adults with ...

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Youths receiving tirzepatide had a 2.28 percentage point ...

CHICAGO, IL—Tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and worsening heart failure events by nearly 40% over a median follow-up of roughly 2 years in patients with ...

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the ...

HOUSTON — The dual GLP-1/GIP receptor agonist tirzepatide showed significantly greater efficacy than the GLP-1 dulaglutide in the treatment of major kidney outcomes in patients with type 2 diabetes ...